Table 1. Estimates of analytic sensitivity for the four schemes included in the biochemical genetic laboratories proficiency testing program stratified by laboratory location.
| Scheme | Location | Analytic true positivea | Analytic false negativeb | P valuec |
|---|---|---|---|---|
| Amino acids | US | 95.1% (1,122/1,180) (93.9–96.3%) | 4.9% (58/1,180) (3.7–6.1%) | <0.001 |
| International | 89.4% (430/481) (86.7–92.2%) | 10.6% (51/481) (7.9–13.3%) | ||
| Organic acids | US | 93.5% (942/1,007) (92.0–95.1%) | 6.5% (65/1,007) (4.9–8.0%) | 0.043 |
| International | 90.4% (369/408) (87.6–93.3%) | 9.6% (39/408) (6.7–12.4%) | ||
| Acylcarnitine profile | US | 93.1% (471/506) (90.9–95.3%) | 6.9% (35/506) (4.7–9.1%) | 0.060 |
| International | 88.9% (192/216) (84.7–93.1%) | 11.1% (24/216) (6.9–15.3%) | ||
| Mucopolysaccharides | US (Screening) | 93.0% (318/342) (90.3–95.7%) | 7.0% (24/342) (4.3–9.7%) | 0.056 |
| International (Screening) | 88.2% (179/203) (83.7–92.6%) | 11.8% (24/203) (7.4–16.3%) | ||
| US (Fractionation) | 91.4% (213/233) (87.8–95.0%) | 8.6% (20/233) (5.0–12.2%) | 0.0010 | |
| International (Fractionation) | 79.0% (94/119) (71.7–86.3%) | 21.0% (25/119) (13.7–28.3%) |
a
Proportion of correct abnormal analyte identified (analytic sensitivity).
b
Proportion of incorrect abnormal analyte identified, or no abnormal analyte identified.
c
Comparison of analytic sensitivity between US and international participants.